Yibin Dai

Yibin Dai

Auto-generated profile, based on publicly available information

Yibin Dai

Oromaxillofacial Head and Neck Surgery Center for Oromaxillofacial Head and Neck Disorders Huashan Hospital Fudan University Shanghai China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YDYibin Dai
Yibin Dai
ZWZiyu Wang
Ziyu Wang
YXYingchao Xia
Yingchao Xia
JLJin Li
Jin Li
YWYaping Wu
Yaping Wu
JCJie Cheng
Jie Cheng
Purpose: Tumor heterogeneity in head and neck squamous cell carcinoma (HNSCC) profoundly compromises patient stratification, personalized treatment planning, and prognostic prediction, which underscores the urgent need for more effective molecular subtyping for this malignancy. Here, we sought to define the intrinsic epithelial subtypes for HNSCC by integrative analyses of single-cell and bulk RNA sequencing datasets from multiple cohorts and assess their molecular features and clinical significance. Experimental Design: Malignant epithelial cells were identified from single-cell RNA sequencing (scRNA-seq) datasets and subtyped on the basis of differentially expressed genes. Subtype-specific genomic/epigenetic abnormalities, molecular signaling, genetic regulatory network, immune landscape, and patient survival were characterized. Therapeutic vulnerabilities were further predicted on the basis of drug sensitivity datasets from cell lines, patient-derived xenograft models, and real-world clinical outcomes. Novel signatures for prognostication and therapeutic prediction were developed by machine learning and independently validated. Results: Three intrinsic consensus molecular subtypes (iCMS1–3) for HNSCC were proposed from scRNA-seq analyses and recapitulated in 1,325 patients from independent cohorts using bulk-sequencing datasets. iCMS1 was characterized by EGFR amplification/activation, stromal-enriched environment, epithelial-to-mesenchymal transition, worst survival, and sensitivities to EGFR inhibitor. iCMS2 was featured by human papillomavirus–positive oropharyngeal predilection, immune-hot, susceptibilities to anti–PD-1, and best prognosis. Moreover, iCMS3 displayed immune-desert and sensitivities to 5-FU and MEK, STAT3 inhibitors. Three novel, robust signatures derived from iCMS subtype-specific transcriptomics features were developed by machine learning for patient prognostication and cetuximab and anti–PD-1 response predictions. Conclusions: These findings reiterate molecular heterogeneity of HNSCC and advantages of scRNA-seq in pinpointing cellular diversities in complex cancer ecosystems. Our HNSCC iCMS regime might facilitate accurate patient stratification and individualized precise treatment.

3 July 2024 in Cancer Research
Verified
Journal Article
Closed access
PDPengfei Diao
Pengfei Diao
YDYibin Dai
Yibin Dai
AWAn Wang
An Wang
XBXiaoxuan Bu
Xiaoxuan Bu
ZWZiyu Wang
Ziyu Wang
JCJie Cheng
Jie Cheng
Substantial heterogeneity in molecular features, patient prognoses, and therapeutic responses in head and neck squamous cell carcinomas (HNSCC) highlights the urgent need to develop molecular classifications that reliably and accurately reflect tumor behavior and inform personalized therapy. Here, we leveraged the similarity network fusion bioinformatics approach to jointly analyze multiomics datasets spanning copy number variations, somatic mutations, DNA methylation, and transcriptomic profiling and derived a prognostic classification system for HNSCC. The integrative model consistently identified three subgroups (IMC1-3) with specific genomic features, biological characteristics, and clinical outcomes across multiple independent cohorts. The IMC1 subgroup included proliferative, immune-activated tumors and exhibited a more favorable prognosis. The IMC2 subtype harbored activated EGFR signaling and an inflamed tumor microenvironment with cancer-associated fibroblast/vascular infiltrations. Alternatively, the IMC3 group featured highly aberrant metabolic activities and impaired immune infiltration and recruiting. Pharmacogenomics analyses from in silico predictions and from patient-derived xenograft model data unveiled subtype-specific therapeutic vulnerabilities including sensitivity to cisplatin and immunotherapy in IMC1 and EGFR inhibitors (EGFRi) in IMC2, which was experimentally validated in patient-derived organoid models. Two signatures for prognosis and EGFRi sensitivity were developed via machine learning. Together, this integrative multiomics clustering for HNSCC improves current understanding of tumor heterogeneity and facilitates patient stratification and therapeutic development tailored to molecular vulnerabilities. Significance: Head and neck squamous cell carcinoma classification using integrative multiomics analyses reveals subtypes with distinct genetics, biological features, clinicopathological traits, and therapeutic vulnerabilities, providing insights into tumor heterogeneity and personalized treatment strategies.


6 August 2026 in Advanced Science
Verified
Journal Article
Open access
FZFangxing Zhu
Fangxing Zhu
YYYuanhe You
Yuanhe You
YZYiyi Zhang
Yiyi Zhang
YDYibin Dai
Yibin Dai
XZXinyu Zhou
Xinyu Zhou
TZTongchao Zhao
Tongchao Zhao
Oral squamous cell carcinoma (OSCC) remains a highly aggressive malignancy with limited responsiveness to anti‐PD‐1 immunotherapy. Recent neoadjuvant studies combining VEGFR‐2 inhibition (VEGFR2i) with anti‐PD‐1 (aPD‐1) have yielded markedly improved pathological responses, suggesting a VEGFR‐2‐dependent immunoregulatory mechanism. Here, we identify a PD‐L1‐expressing CD66b + neutrophil‐enriched tumor‐associated population as a critical immunosuppressive population enriched in VEGFR‐2‐high OSCC tumors and associated with increased metastatic propensity and inferior patient outcomes. Using multiplex immunohistochemistry, scRNA‐seq, and flow cytometry, we demonstrate that VEGFR‐2‐overexpressing OSCC cells drive robust GM‐CSF secretion, which in turn induces PD‐L1 upregulation in neutrophils. Mechanistically, VEGFR‐2 activation promotes STAT6 phosphorylation and nuclear translocation, enabling direct transcriptional activation of CSF2 . GM‐CSF subsequently activates STAT5 and mTOR/S6K signaling in neutrophils, thereby enhancing PD‐L1 protein synthesis. Functionally, these PD‐L1 + TANs suppress CD8 + T‐cell proliferation, augment T‐cell exhaustion, and diminish cytotoxicity. Importantly, VEGFR‐2 inhibition or GM‐CSF neutralization restored CD8 + T‐cell function and improved responsiveness to anti‐PD‐1 therapy in vivo, whereas exogenous GM‐CSF impaired VEGFR2i/aPD‐1 efficacy. Collectively, our findings reveal a previously unrecognized VEGFR‐2/STAT6/ CSF2 axis that licenses neutrophil‐mediated immune suppression in OSCC. These data provide mechanistic rationale and preclinical support for targeting the VEGFR‐2/GM‐CSF‐neutrophil axis to improve the efficacy of PD‐1 blockade in OSCC.


17 June 2026
Verified
Other
Open access
PDPengfei Diao
Pengfei Diao
YDYibin Dai
Yibin Dai
AWAn Wang
An Wang
XBXiaoxuan Bu
Xiaoxuan Bu
ZWZiyu Wang
Ziyu Wang
JCJie Cheng
Jie Cheng
Supplementary Data from Integrative Multiomics Analyses Identify Molecular Subtypes of Head and Neck Squamous Cell Carcinoma with Distinct Therapeutic Vulnerabilities